IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases. In addition, there has been a substantial increase in IVIG prescriptions for the treatment of off-label indications, such as, specific antibody deficiency, Guillain-Barre syndrome, Inflammatory Myopathies and others. However, factors such as the high cost of IVIG treatment, side effects associated with use of IVIG, stringent government regulations and a lengthy product approval process would hamper its market growth. Despite several challenges such as inadequate supply of immunoglobulins, stringent regulatory policies and the high cost associated with IVIG treatments, the global IVIG market would witness notable growth during the forecast period.
Global IVIG market is segmented based on its types, application and geography. The application segment includes Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia (CLL), Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome, and others. Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP) holds a dominant share in the market due to a large patient population and the unavailability of effective alternatives for IVIG treatment. Geographically, the report covers five key regions, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies a majority of the market followed by the Asia Pacific region. High adoption of IVIG therapies and a large pool of patient population in the North American region is a prime factor responsible for the growth of the North America IVIG market. However, in the Asia-pacific region, growing awareness for immunodeficiency disease & neurological disorders along with the increasing preference towards IVIG therapies, largely drives the market. The companies profiled in this report include Baxter international Inc., CSL Limited, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others.
KEY MARKET SEGMENT:
Global IVIG market is segmented based on the application, types and geography
MARKET BY APPLICATION
MARKET BY TYPE
MARKET BY GEOGRAPHY
SIMILAR MARKET STUDIES
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in the cord ...
July 2017 | $5370 | View Details >>
Cancer Vaccines Market by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines), Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer, and Others), and End Use (Pediatrics and Adults) - Global Opportunity Analysis and Industry Forecast, 2017-2023
A vaccine is a biological preparation that strengthens the immune system and provides acquired immunity against a specific pathogen. According to the World Health Organization (WHO), cancer vaccines are popularly for treating various types of cancer such as, breast cancer, lung cancer, cervical cancer, and others. The key factors that ...
July 2017 | $5370 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research